The Use of Probiotic Dietary Supplementation to Alter the Intestinal Microbiota and Improve Growth in Children with Short Bowel Syndrome
Study ID: STU 042016-047
all eligible children will be consented at the time of an outpatient clinic visit or during an inpatient stay. enrolled participants will then be randomized to [Quote]placebo[Quote] where they will receive pure Medium Chain Triglyceride (MCT) oil daily for 3 months, or [Quote]probiotic therapy[Quote] where they will receive a probiotic daily for 3 months in addition to the standard of care. Stool (approximately 200mg per sample) will be collected at 3 separate time points for each patient (at the beginning, midpoint and end of the study) and fecal 16S rRna microbial sequencing, SCFa concentrations and metabolomics analysis will be compared between groups, as will the groups growth trajectory. a stool sample will also be collected at the beginning of the study from 10 [Quote]control[Quote] subjects (children with short bowel syndrome who are growing well) and will be used for 16S rRna sequencing and metabolomics analysis. The primary outcome of the study will be the change in the abundance of intestinal Lactobacillus in children with SBS after supplementation with targeted probiotics compared to children with SBS not receiving probiotics. The secondary outcomes will be the change in concentration of SCFas in the stool between the treatment group receiving probiotics and the placebo group, and changes in z scores for both weight, height, and BMi during the study period.
Children (<18 years old) will be eligible for the study if they: a.Have a diagnosis of SBS (<25% of their expected small bowel length based on age, or >6 weeks of parenteral nutrition after small bowel resection) b.Are cared for by the Intestinal Rehabilitation Team at Children[Single Quote]s Medical Center c.Are receiving at least a portion of calories from enteral nutrition